Latest Australian Markets News

Barramundi Limited (NZX:BRM) has reported the worst performance in its 20-year history, with a NZ$42.9 million net loss and a 17.0% fall in gross portfolio performance. The board is reviewing Fisher Funds’ management performance just weeks before its five-year agreement comes up for renewal.

BCAL Diagnostics has begun introducing ClearNote Health’s Avantect Multi-Cancer blood test in Australia, starting with Sydney and Melbourne. The test reported 56.2% sensitivity and 98.4% specificity in a case-control validation study, but the company says a negative result does not rule out cancer.

S&P Dow Jones Indices has announced its September 2026 quarterly rebalance for the S&P/ASX indices, with significant reshuffling across major benchmarks effective before market open on September 21.

Immuron Limited has inked an exclusive US distribution deal for PROIBS®, a European-certified medical device targeting abdominal discomfort, marking a key step in its digestive health portfolio growth.

Ramsay Health Care has finalised its $251 million purchase of National Capital Private Hospital in Canberra, expanding its footprint in key therapeutic areas and expecting earnings accretion within a year.

MyEco Group has trimmed its net loss by 8.1% in FY26, driven by a strategic shift toward higher-margin sustainable consumer products and operational cost savings. Australian retail sales surged 22.7%, underpinning a stronger revenue mix and improved cash flow.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

Foley Wines reported a 258% surge in net profit for FY2026 despite a 5.4% decline in bottled sales revenue, driven by a premiumisation strategy and cost controls.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

NEXTDC has swung to a statutory profit of $82.1 million in FY26, driven by a record 202% jump in contracted utilisation and a strategic shift in lease accounting that added a $128.8 million fair value gain. The company’s $3.4 billion capital expenditure underscores its aggressive expansion, including the opening of its first international data centre in Kuala Lumpur.

Associate Global Partners (ASX:APL) reported a 20% rise in funds under management to $1.672 billion for FY2026, driven by strong inflows and new partnerships with Muzinich and ARK Invest.

Tourism Holdings Limited (thl) posted a $39.9 million statutory net profit after tax for FY26, reversing a prior year loss, while navigating geopolitical headwinds and receiving competing takeover bids.